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ABSTRACT
Objective: The present work was aimed to prepare and evaluate polymeric nanoparticles (NPs) of flutamide by nanoprecipitation method and 
factorial. The influences of various formulation components such as polymer, organic phase volume, and surfactant on the characteristics of NPs were 
investigated.
Methods: The polycaprolactone (PCL) loaded with drug was evaluated for surface morphology, surface charge, particles size, encapsulation efficiency, 
drug content, and in vitro release studies. Fourier transform infrared studies were indicated no interaction between the drug and polymer.
Results: The results of the drug release study of NPs may fit with different kinetic equations. The particle size varied from 128 to 317 nm and zeta 
potential was in negative and its value found to be - 46.4 mv. The content of flutamide was found in between 74%±0.72 to 92%±0.53 in  flutamide 
loaded PCL NPs. The minimum and maximum entrapment efficiencies were found to be of 75%±0.66 and 92%±0.70. The percentage yields of all 
formulations were in the range of 46.05%±1.56–86.78%±1.32. The in vitro drug release followed zero order with sustained behavior for a period of 
24 h. Results of accelerated storage conditions of optimized formulation revealed that no significant changes in formulation F2.
Conclusion: The present investigation opens new frontiers in developing flutamide NPs for targeting delivery to the prostate for the prostate cancer 
treatment which also overcome the problems associated with conventional formulations such as multiple-dose therapy, poor patient compliance, and 
high treatment cost.
Keywords: Nanoprecipitation method, Polymeric nanoparticles, Prostate cancer.
INTRODUCTION
Among all types of cancers, prostate cancer stands sixth by being fatal 
to men all over the world. By 2030, prostate cancer is likely to increase 
manifold, by 1.7 million new patients and 499,000 deaths, increase 
and aging of population being the reasons [1]. It is mostly observed in 
men between 65 and 75 years of age, with 25% of the total number 
in men <65 years. Surgery, hormone therapy, radiation therapy, and 
chemotherapy are the treatments presently available to cure this 
deadly disease, which are either invasive or cause severe side effects.
Advanced prostate cancer is treated using flutamide, an effective 
nonsteroidal antiandrogen. The androgen receptors on the cancer 
cells are blocked and inhibit the growth of the cells dependent on 
androgens. Usually, flutamide is prescribed 250 mg as oral dose, thrice 
a day as its oral absorption is fast and reaches the highest level of 
plasma concentration in 1 h after giving the dose [2]. The drug has high 
first-pass hepatic metabolism and low elimination half-life of 5–6 h. 
Low functionality of flutamide is due to its rapid metabolism, less 
active metabolites (hydroxyl flutamide), and low bioavailability. Low 
bioavailability may be due to its reduced wettability and low solubility 
in water which reduces testosterone only on a continuous basis. 
Moreover, high dose of flutamide produces hepatotoxicity. Diarrhea, 
fatigue, impotence, enlargement of male breast, and malfunction of 
liver may be included among the side effects caused with the use of 
flutamide. A sustained release formulation of flutamide can be adopted 
to lessen the rate of drug administration and also to minimize the 
undesirable effects. Hence, the preparation of flutamide formulations 
with high plasma half-life, slow and constant release which can deliver 
to the target tissue is important. Preparation of nanoparticles (NPs) is 
a method that makes it possible to increase the bioavailability. It also 
helps in reducing the occurrence and harshness of adverse effects, 
significantly lessening the gastrointestinal disorders and hepatic 
problems [3].
The novel controlled release polymeric NPs with the active agent improve 
its bioavailability and compliance, leading to the lessening of drug toxicity 
and adverse effects. Due to their daily usage, low bioavailability or high 
toxicity and parenteral controlled release systems gain significance for 
drugs [4]. To progress compliance, biodegradable injectable delivery 
system can be used to transport drugs and to safeguard the blood level 
in a required therapeutic range for a long duration. The conventional 
dosage forms have a lesser advantage when compared to the design of 
the controlled release NPs. The following are the advantages of using the 
novel design of the controlled release NPs [5]:
•	 The	frequency	of	drug	administration	is	controlled
•	 Fluctuations	in	drug	level	are	lessened
•	 The	 total	drug	used	 in	 comparison	 to	 conventional	 treatment	 is	
reduced
•	 Drug	toxicity	levels	are	reduced	(local/systemic)
•	 Medical	condition	is	stable due to the uniformity in drug levels
•	 Economical	for	pharmacists	and	patients.
Many varieties of polymers are used in the field of pharmacy for 
controlled drug delivery. Synthetic manipulation of these is used in 
many applications as in biofilms, nanoparticles, and microparticles. 
Poly-D, L-lactide-co-glycolide (PLGA), polylactic acid (PLA), or 
polycaprolactone (PCL) are the most common polymers which are 
made use of. In the present study, PCL was chosen as the material for 
the	particle	matrix.	−60°C	is	its	glass	transitions	temperature	which	is	
very	 low	and	 its	melting	point	 ranges	 from	59	 to	64°C	depending	on	
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chain length (molecular weight). In targeted cancer therapy, PCL is the 
ideal material for controlled drug delivery, as its permeable to many 
drugs and is not toxic [6]. Its biocompatibility with a slow degradation 
rate makes it ideal for long-term delivery. It is widely used in the 
pharmaceutical industry due to its being a semi-crystalline polymer and, 
therefore, used for long-standing drug delivery systems which target 
the specific tissues of the body. As it is cheap and has reduced levels 
of toxicity, it is most economical and viable among the three polymers 
(PLGA, PLA, and PCL) [7]. At present, hormone-altering drug (FLT) is 
not encapsulated within PCL NPs. To instigate controlled release of the 
active agent, these types of drugs are ideal to be encapsulated within 
PCL NPs. In the human body, the polymer PCL undergoes hydrolysis of 
the ester linkages and is observed to have a slower rate of degradation 
compared to the other polymers derived from lactides [8].
Hence, the present study was aimed to the preparation of flutamide-
loaded PCL NPs using nanoprecipitation method and evaluation of NPs 
for its physiochemical characteristics and in vitro release studies.
METHODS
Flutamide was purchased from Yarrow Chem Products, Mumbai. 
PCL and Pluronic F-127 purchased from Coastal Chemical Limited, 
Visakhapatnam, and all other ingredients used were of analytical grade 
obtained from obtained from Qualigens Fine Chem, Mumbai.
Preformulation studies
Organoleptic properties
Flutamide was evaluated for organoleptic properties such as 
appearance and color.
Solubility analysis
The solubility of flutamide was checked in water and it was confirmed 
by quantitative determination using ultraviolet (UV) spectroscopy at 
228 nm.
Melting point determination
Melting point is the first indication of purity of the sample and the 
presence of small amount of the impurity can be detected by lowering 
or widening the melting point range.
Identification of pure drug
Fourier-transform infrared (FTIR) spectroscopy was used for the 
identification of flutamide.
Determination of λmax
Preparation of stock solution
About 10 mg of flutamide was transferred in a 100 ml volumetric 
flask and methanol was added in small proportion (20 ml) to dissolve 




and the solution was scanned between 400 and 200 nm to determine 
the	λ	max.
Compatibility study
A stable and effective dosage form was formulated depends on selection 
of excipients that are promote the drug release and bioavailability 
and protect it from degradation. If the excipients not were used in 
formulation containing the active drug, the compatibility study is 
mandatory.
Drug-polymer compatibility studies by FTIR
IR spectra of flutamide and formulation mixture were recorded 
by dispersion of drug and polymer in suitable solvent using FTIR 
spectrophotometer. A baseline was made using dried KBr, and then, the 
spectra of mixture of drug, polymer mixture, and KBr were recorded 
on FTIR [9].
Calibration of standard curve
In 100 ml of pH 7.4 phosphate buffer solution, 100 mg of accurately 
weighed flutamide was dissolved. 10 ml of this solution was further 
diluted with 7.4 pH phosphate buffer to get 100 µg/ml solutions. From 
the above stock solution, different concentrations (2–20 µg/ml) were 
prepared with pH 7.4 phosphate buffer. From each concentration, 
sample was taken and the absorption was measured at 228 nm 
using UV spectrophotometer and pH 7.4 phosphate buffer as a blank. 
The calibration curve was plotted and the regression equation and 
correlation coefficient were determined.
Preparation of NP’S
23 Factorial design
The optimization phase was carried out statistically using 23 factorial 
design in which the polymer concentration, stabilizer, and organic 
solvent volume were kept at two different levels (Table 1). The eight 
formulations were categorized into four groups (given below) for ease 








Flutamide-loaded PCL NPs were prepared by the nanoprecipitation 
method [10]. This method involves the precipitation of polymer from an 
organic solvent and diffusion of organic solvent into aqueous phase in the 
presence of a surfactant. PCL and flutamide were dissolved in acetone 
and this solution was added to Pluronic F-127 in PBS pH 7.4 at 1 ml/min 
speed using syringe under magnetic stirring conditions. The obtained 
suspension was stirred at 500 rpm for 2 h to evaporate acetone. The 
suspension was cooling centrifuge at 11,000 rpm for 30 min to remove 
precipitants and supernatant was collected, lyophilized, and stored at 
4°C.	Repeated	the	procedure	by	varied	in	the	concentrations	of	polymer,	
stabilizer, and organic solvent volume to optimize the formulation. Blank 
NPs were prepared by the same procedure but excluding flutamide.
Characterization of prepared NP’s
The obtained formulations of flutamide-loaded PCL NPs were 
characterized for following parameters.
Particle size analysis and surface morphology
Particle size analysis
Particle size measurement was carried out by Photon Correlation 
Spectroscopy (PCS) (Malvern Instruments). Samples were diluted 
with	ultra-purified	water,	measured	at	25°	and	90°	scattering	angles,	
recorded for 180 s and the mean diameters for all samples were 
obtained by cumulative analysis in triplicate.
The morphological study of NPs was carried out using scanning 
electron	microscopy	(SEM)	(Tecnai	20	G2	S	TWIN).	SEM	was	employed	
to understand the arrangement and orientation of molecules within the 




EE	percentage	is	also	known	as	association	efficiency [12]. This was 
studied by centrifuging the drug-loaded NPs at a high speed of 3500– 
4000 rpm for 30 min and the supernatant was assayed for free drug 
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concentration	 using	 spectrophotometer.	 EE	was	 then	 calculated	 as	
follows:
Actual amount of drug added raUnbound drug  (Free drug) EE	% 	100
Actual amount of drug added
= ×
Drug content
Free drug in the supernatant (drug content) was estimated by 
centrifuging	 the	 NPs	 suspension	 at	 15,000	 rpm	 for	 40	min	 at	 25°C.	
Concentration of flutamide present in the supernatant was determined 
by UV spectrophotometer at 228 nm [13].
Percentage yield
It was determined by the equation [12].
Weight	of	dried	nanoparticles	recovered	Percentage yield 100
Sum of initial dry weight of starting material 
= ×
In vitro release studies
In vitro release profile of the prepared NP suspensions was studied 
by diffusion method using an artificial membrane. In the donor 
compartment, nanosuspension containing known concentration of 
drug (20 mg) was placed, and in the receptor compartment, pH 7.4 
phosphate buffer was placed and constantly agitated using a magnetic 
stirrer	at	100	rpm	and	37°C.	0.5	ml	samples	were	withdrawn	from	the	
receptor compartment for the estimation of released drug and replaced 
with similar volume of buffer. This study was carried out for 24 h, and 
the concentration of drug released was determining the absorbance at 
228 nm using UV spectrophotometer [10].
Kinetic modeling
To understand the kinetics and mechanism of drug release from 
optimized formulation F2, the results of in vitro release study were 
fitted with zero-order, first-order, and Higuchi’s model [14].
Stability study
The stability study was carried for the formulation F2. The stability 
was	 determined	 in	 terms	 of	 its	 drug	 content,	 EE,	 and	 in vitro drug 
release. The formulation was incubated for a period of 6 monthsat 
37±1°C	 [10],	 and	 at	 specified	 time	 intervals,	 the	 suspension	 was	
centrifuged at 4000 rpm for 1 h. The amount of drug present in the 
Fig. 1: Infrared spectra of flutamide
Fig. 2: λmax of flutamide
Fig. 3: Infrared spectra of flutamide
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Flutamide has got buff to yellow color, unpleasant smell and found to be 
very fine crystalline powder.
Solubility studies
Flutamide was low soluble in water and freely soluble in organic 
solvents. The solubility in water was found to be 0.0094 mg/ml.
Melting point determination
The melting point of pure drug flutamide was determined in the range 
of	111–113°C	by	capillary	method.
Identification of pure drug
FTIR spectrum of flutamide in Fig.1 has showed the peaks at 3355, 
1709, 1509, 1314, and 654 cm−1. The absorption bands between 3250 
and 3400 cm−1 were indicated the presence of –NH stretching. The wave 
numbers observed at 1709 and 1314 may be assigned to the C = O and 
C - N bonds, respectively, and the sharp peak occurred at 1509 and 654 
indicate the presence of N = O and C – F3 group attached to C = C.
Determination	of	λmax
The flutamide with pH 7.4 PBS was scanned between 400 and 200 nm 
with	UV-vis	spectrophotometer	and	the	λmax was found to be at 228 nm. 
Hence, the standard curve of flutamide was developed at 228 nm (Fig. 2).
Drug-excipient compatibility studies
FTIR spectroscopy
FTIR studies used to determine the interaction between drug and 
excipients used in NP preparation. The mixture of drug and excipients 
was prepared in 1:1 w/w ratio and used for IR analysis.
IR spectra of flutamide were recorded over than 600–4000 cm−1 using 
Brooker spectrophotometer with KBr pellet method.
Inference
IR spectra of formulation had showed absorption peaks (Figs. 3 and 4)
which were comparable with absorption peaks of pure drug. The peaks 
indicated that, no chemical interaction between drug and excipients.
Standard graph of flutamide
The standard curve of flutamide was done using pH 7.4 PBS as the 
medium and the maximum absorbance was found at 228 nm. The 
standard graph was constructed between 2 and 20 µg/ml concentrations. 
Absorbances were examined under UV-visible spectrophotometer at an 
Fig. 4: Infrared spectra of flutamide + polycaprolactone + Pluronic F 127
Table 1: 23 Factorial design of NPs
Factor Low level (−1) High level (+1)
Polymer 10 mg 50 mg
Stabilizer 1% 1.5%
Organic solvent 10 ml 30 ml
Table 2: Drug entrapment efficiency









Mean±SD of three determinations. SD: Standard deviation
Table 3: Percentage yield









Mean±SD of three determinations. SD: Standard deviation
Table 4: Accelerated stability studies of optimized formulations F2
Parameter Code 0 day 30 days 60 days 90 days
Drug content F2 92±0.70 91±0.23 90±0.24 90±0.21
Entrapment	efficiency	(%) F2 92±0.53 91±0.05 91±0.26 90±0.84
In vitro drug release (%) F2 77%±1.32 76%±1.54 75%±1.72 74%±1.63
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absorption maximum of 228 nm. The standard graph was constructed 
by taking the absorbance on Y-axis and concentrations on X-axis. Drug 
concentration and absorbance followed linear relationship the curve 
obeyed Beer–Lambert’s law, and the correlation coefficient value (R2) 
is 0.998.
Preparation of NPs
Nanoprecipitation method was used for the preparation of flutamide-
loaded NPs. The formulations were designed by 23 factorial design, 
which contained three variables such as polymer concentration, 
stabilizer, and organic solvent volume at two levels. Total eight batches 
were formulated (F1-F8) and all the formulations were investigated for 
various parameters.
Characterization of prepared NPs
Size analysis
Eight	 formulations	were	 developed	 by	 varying	 the	 concentrations	 of	
polymer, stabilizer, and volume of organic solvent at two levels, and 
the effect on particle size was determined (Figs. 5 and 6). Formulation 
F7 showed minimum particle size of 128 nm and the formulation F2 
showed maximum particle size of 317 nm. The results indicate that the 
particle size increased with increasing polymer (PCL) concentration of 
10 and 50 mg due to agglomeration of the particles [15]. The particle 
size decreased with increasing organic phase volume of 10 and 30 ml 
and the particle size decreased with increasing Pluronic F-127 from 1% 
to 1.5%.
Fig. 5: Size analysis of nanoparticles formulations F1-F8
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SEM
SEM	 image	 (Fig.	 7),	 F1	 shown	 formed	NPs	 at	 an	 average	 diameter	
of	194	nm	with	a	minute	amount	of	wrinkles	on	the	surface.	While	
the image of F2 shown two different sizes with less uniformity. The 
image also displays a large amount of larger NPs surrounding the 
smaller NPs with average diameter of 317 nm. On observing image 
F3 and F4 showed NPs at an average diameter of 190 nm and 217 nm. 
Image F5 showed a complete spherical-shaped NP at an average 
diameter of 148 nm. Image F6 showed NPs at an average diameter 
of 297 nm that have minimal wrinkles or porous structure on the 
exterior. Image F7 showed fully formed spherical-shaped smooth NPs 
with	 an	 average	diameter	 of	 128	nm.	 SEM	 image	 F8	 shown	NPs	 at	
an average diameter of 211 nm that have some wrinkles or porous 
structure on the exterior.
Surface charge (zeta potential)
The zeta potential of the formulation F7 F7 shown in Fig. 8 was found to 
be - 46.4, which implies that it is having good stability. The negative zeta 
potential values of formulation F7 can be attributed to the presence of 
uncapped end ionized carboxyl groups of the polymer at the particle 
surface [16].
Drug content
NPs obtained from F2 formulation showed maximum drug content 
(92%±0.53) and F7 showed minimum drug content (74%±0.72). Drug 
content was increased with increasing polymer concentration of 10 
and 50 mg. It was decreased with increased acetone volume of 10 and 
30 ml and decreased significantly with increasing amount of surfactant 
Pluronic F-127. The drug content of NPs were shown in Fig. 9.
EE
On increasing the polymer concentration, increasing (10 and 50 mg) 
EE	was	observed,	whereas	increase	in	acetone	volume	(10	and	30	ml)	
has	 slightly	 decreased	 the	 EE,	 and	 increase	 in	 surfactant	 Pluronic	
F127	(1%–1.5%	w/v)	has	significantly	decreased	EE.	Drug	EE	varied	
from 75%±0.66 to 92%±0.70 (Table 2). The formulation F2 stabilized 
with 1% w/v Pluronic F127 and 1:1 ratio of organic phase:aqueous 
phase	volume	showed	maximum	EE	92%±0.70.
Percentage yield
The percentage yield of NPs prepared by nanoprecipitation method was 
recorded and shown in Table 3,  it was  determined by collecting the NPs 
and weighed. The measured weight was divided by the initial dry weight 
of starting materials, which were used for the preparation of the NPs. 
It was found that when concentration of PCL increased, the percentage 
yields also increased. It was decreased with increased organic phase 
acetone volume and increased significantly with increasing amount 
of surfactant Pluronic F-127. The percentage yields of NPs of all 
formulations were in the range of 46.05%±1.56–86.78%±1.32. The 
formulation F6 containing 50 mg PCL and 1:1 ratio organic:aqueous 
phase volume with 1.5% Pluronic F-127 showed maximum percentage 
yield of 86.78%±1.32 compare to other formulations.
In vitro release studies
The flutamide PCL NPs have exhibited fast release in the first 4 h and 
slow/continuous sustained release in the next 20 h. The fast release 
of drug was attributed to surface associated drug, whereas the slow 
release was attributed to the drug entrapment in NPs. The drug release 
was slowed down due to the increased viscosity and diffusion path as 
the polymer ratio was increased. This was because of high polymer 
concentration (50 mg PCL - F2, F4, F6, and F8) showed slow drug 
release for more than 24 h (Fig. 10b). Low polymer concentration 
(10 mg PCL - F1, F3, F5, and F7) showed almost complete drug release 
within 24 h (Fig. 10a).
Increase in organic phase volume increases the rate of release of the 
drug (Fig. 10d) due to increased diffusivity and hydrodynamics at 
the interface. A slight rise in drug release was noticed, Pluronic F127 
concentration was increased (Fig. 10f). The size of NP plays a major 
role in drug release, i.e., smaller the size of NPs higher the drug release 
rates. The formulation F7 containing particle size of 128 nm had shown 
maximum drug release of 98.23%±1.24 compare to other formulations.
The flutamide NPs (F2) prepared with 50 mg PCL, 10 ml acetone, and 
1% Pluronic F127 had shown better controlled and sustained drug 
Fig. 6: Mean particle size analysis of nanoparticle formulations 
F1-F8
Fig. 7: Scanning electron micrographs of nanoparticles 
formulations F1-F8
Fig. 8: Zeta potential of nanoparticles formulation F7
Fig. 9: Percentage drug content of nanoparticle formulations 
F1-F8
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release	of	77.42%±1.32	within	24	h.	From	the	results	of	EE	(92%),	drug	
content (92%), and in vitro release studies (77.42%), formulation F2 
was considered as optimized trial.
Kinetic modeling of drug release
The exact mechanism of drug release of F2 formulation was subjected 
to kinetic models. The R2 value of zero order and first order was found 
as 0.939 and 0.923, respectively. This result suggests that the drug 
released by zero-order kinetics. The R2 value of Higuchi’s and Peppas 
diffusion equation was obtained as 0.993 and 0.710, respectively. This 
result suggests that the drug released followed diffusion mechanism.
Accelerated stability studies
The optimized formulation F2 was sealed in an aluminum foil and 
subjected to stability studies. The result showed in Table 4, that there 
were no  significant changes occur during storage after 90 days.
CONCLUSION
Polymeric NPs of flutamide were successfully prepared and evaluated 
by nanoprecipitation method and factorial design. The influences 
of various formulation components such as polymer, organic phase 
volume, and surfactant on the characteristics of NPs were investigated. 
Esthetic	results	proved	that	formulation	F2	containing	50	mg	PCL	and	
10 ml acetone with 1% Pluronic F127 produced the most ideal NPs with 
encapsulation efficiency and controlled drug release within 24 h. This 
suggest that, the daily administration of single low dose of F2 NPs, as 
the rate of release of prepared flutamide NPs is less than the half-life of 
free flutamide (8 h). Therefore, this investigation opens new frontiers 
in developing flutamide NPs for targeting delivery to the prostate for 
the prostate cancer treatment which also overcome the problems 
associated with conventional formulations such as multiple dose, high 
treatment cost, and poor patient compliance.
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